Revolutionizing cardiovascular care: the role of natriuretic peptides and neprilysin inhibition

1 World Health Organization. “Cardiovascular Diseases.” Accessed [1.09.2024]. Available from: https://www.who.int/health-topics/cardiovascular-diseases#tab=tab_1 Search in Google Scholar

2 Goff DC, Lloyd-Jones DM, Bennett G, Coady S, D’Agostino RB, Gibbons R, Greenland P, Lackland DT, Levy D, O’Donnell CJ, Robinson JG, Schwartz JS, Shero ST, Smith SC, Sorlie P, Stone NJ, Wilson PWF. 2013 ACC/AHA guideline on the assessment of cardiovascular risk. Circulation. 2014;129(25 suppl 2): S49-73; DOI:10.1161/01.cir.0000437741.48606.98. Search in Google Scholar

3 Biomarkers Definitions Working Group. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther. 2001;69(3):89-95; DOI:10.1067/mcp.2001.113989. PMID: 11240971. Search in Google Scholar

4 Redberg RF, Vogel RA, Criqui MH, Herrington DM, Lima JAC, Roman MJ. Task force #3 -what is the spectrum of current and emerging techniques for the noninvasive measurement of atherosclerosis?. J Am Coll Cardiol. 2003;41(11):1886-98; DOI:10.1016/S0735-1097(03)00360-7. Search in Google Scholar

5 Strimbu K, Tavel JA. What are biomarkers?. Current Opinion in HIV and AIDS. 2010;5(6):463-6; DOI:10.1097/COH.0b013e32833ed177. Search in Google Scholar

6 Panagopoulou V, Deftereos S, Kossyvakis C, Raisakis K, Giannopoulos G, Bouras G, Pyrgakis V, W.Cleman M. NTproBNP: An important biomarker in cardiac diseases. CTMC. 2013;13(2):82-94; DOI:10.2174/15680266 11313020002. Search in Google Scholar

7 Vuolteenaho O, Ala-Kopsala M, Ruskoaho H. BNP as a biomarker in heart disease. Adv Clin Chem. 2005;40:1-36. Search in Google Scholar

8 McMurray JJV, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Solomon SD, Swedberg K, Zile MR. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014;371(11):993-1004; DOI:10.1056/NEJMoa1409077. Search in Google Scholar

9 Maisel AS, Krishnaswamy P, Nowak RM, McCord J, Hollander JE, Duc P, Omland T, Storrow AB, Abraham WT, Wu AHB, Clopton P, Steg PG, Westheim A, Knudsen CW, Perez A, Kazanegra R, Herrmann HC, Mc- Cullough PA. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med. 2002;347(3):161-7; DOI:10.1056/NEJMoa020233. Search in Google Scholar

10 Januzzi JL, Camargo CA, Anwaruddin S, Baggish AL, Chen AA, Krauser DG, Tung R, Cameron R, Nagurney JT, Chae CU, Lloyd-Jones DM, Brown DF, Foran-Melanson S, Sluss PM, Lee-Lewandrowski E, Lewandrowski KB. The N-terminal pro-BNP investigation of dyspnea in the emergency department (PRIDE) study. The Am J Cardiol. 2005;95(8):948-54; DOI: 10.1016/j.amjcard.2004.12.032. Search in Google Scholar

11 Januzzi JL, van Kimmenade R, Lainchbury J, Bayes-Genis A, Ordonez-Llanos J, Santalo-Bel M, Pinto YM, Richards M. NT-proBNP testing for diagnosis and short-term prognosis in acute destabilized heart failure: an international pooled analysis of 1256 patients: the International Collaborative of NT-proBNP Study. Eur Heart J. 2006;27(3):330-7; DOI:10.1093/eurheartj/ehi631. Search in Google Scholar

12 Kim H, Januzzi JL. Natriuretic peptide testing in heart failure. Circulation. 2011;123(18):2015-9; DOI:10.1161/CIRCULATIONAHA.110.979500. Search in Google Scholar

13 Fonarow GC, Peacock WF, Phillips CO, Givertz MM, Lopatin M. Admission B-type natriuretic peptide levels and in-hospital mortality in acute decompensated heart failure. J Am Coll Cardiol. 2007;49(19):1943-50; DOI:10.1016/j.jacc.2007.02.037. Search in Google Scholar

14 Januzzi JL, Sakhuja R, O’Donoghue M, Baggish AL, Anwaruddin S, Chae CU, Cameron R, Krauser DG, Tung R, Camargo CA, Lloyd-Jones DM. Utility of amino-terminal pro-brain natriuretic peptide testing for prediction of 1-year mortality in patients with dyspnea treated in the emergency department. Arch Intern Med. 2006;166(3):315; DOI:10.1001/archinte.166.3.315. Search in Google Scholar

15 Kociol RD, Horton JR, Fonarow GC, Reyes EM, Shaw LK, O’Connor CM, Felker GM, Hernandez AF. Admission, discharge, or change in B-type natriuretic peptide and long-term outcomes: data from Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF) linked to Medicare claims. Circ Heart Fail. 2011;4(5):628-36; DOI:10.1161/CIRCHEARTFAILURE.111.962290. Search in Google Scholar

16 Masson S, Latini R, Anand IS, Barlera S, Angelici L, Vago T, Tognoni G, Cohn JN; Val-HeFT Investigators. Prognostic value of changes in N-terminal pro-brain natriuretic peptide in Val-HeFT (Valsartan Heart Failure Trial). J Am Coll Cardiol. 2008;52(12):997-1003; DOI:10.1016/j. jacc.2008.04.069. PMID: 18786480. Search in Google Scholar

17 Gaggin HK, Januzzi JL. Biomarkers and diagnostics in heart failure. Biochim Biophys Acta. 2013;1832(12):2442-50; DOI:10.1016/j. bbadis.2012.12.014. Search in Google Scholar

18 Januzzi JL Jr, Rehman SU, Mohammed AA, Bhardwaj A, Barajas L, Barajas J, Kim HN, Baggish AL, Weiner RB, Chen-Tournoux A, Marshall JE, Moore SA, Carlson WD, Lewis GD, Shin J, Sullivan D, Parks K, Wang TJ, Gregory SA, Uthamalingam S, Semigran MJ. Use of amino-terminal pro-B-type natriuretic peptide to guide outpatient therapy of patients with chronic left ventricular systolic dysfunction. J Am Coll Cardiol. 2011;58(18):1881-9; DOI:10.1016/j.jacc.2011.03.072. Search in Google Scholar

19 Bayes-Genis A, Barallat J, Richards AM. A test in context: neprilysin: function, inhibition, and biomarker. J Am Coll Cardiol. 2016;68(6):639-53; DOI:10.1016/j.jacc.2016.04.060. Search in Google Scholar

20 Packer M, Califf RM, Konstam MA, Krum H, McMurray JJ, Rouleau JL, Swedberg K. Comparison of omapatrilat and enalapril in patients with chronic heart failure: the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE). Circulation. 2002;106(8):920-6; DOI:10.1161/01.cir.0000029801.86489.50. Search in Google Scholar

21 Richards AM, Wittert GA, Espiner EA, Yandle TG, Ikram H, Frampton C. Effect of inhibition of endopeptidase 24.11 on responses to angiotensin II in human volunteers. Circulation Research. 1992;71(6):1501-7; DOI:10.1161/01.RES.71.6.1501. Search in Google Scholar